Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

BOSTON, August 03, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from its Phase 2 proof-of-concept trials evaluating treatment with the selective, oral NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty and bunionectomy surgeries.

Related Keywords

Boston ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Australia ,London ,City Of ,America ,Heather Nichols ,Carmen Bozic ,Miroslava Minkova ,Scott Weiner ,Facebook ,Companies To Work ,Department Of Emergency Medicine At Brigham ,Global Medicines Development ,Instagram ,Vertex Pharmaceuticals Incorporated ,Twitter ,Linkedin ,Vertex Pharmaceuticals Incorporated Nasdaq ,Youtube ,Exchange Commission ,New England Journal ,Executive Vice President ,Medical Affairs ,Chief Medical Officer ,Associate Professor ,Emergency Medicine ,Harvard Medical School ,Attending Emergency Physician ,Breakthrough Therapy ,Fast Track ,Innovation District ,North America ,Top Employers ,Private Securities Litigation Reform Act ,Vertex Pharmaceuticals ,Neuropathic Pain ,Acute Pain ,Potential ,Preclinical Studies ,Preclinical Data ,Share Results ,